PO004LBA/#1515 Efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer following prior systemic therapy
Grisham R, Aghajanian C, Nieuwenhuysen E, Rodrigues M, Ring K, Santin A, Colombo N, Prendergast E, Thaker P, Moore K, Salinas E, Ray-Coquard I, Chon H, Rose P, Oaknin A, Clamp A, Gandhi M, Monk B, Holloway R, Gorp T, Fabbro M, Gennigens C, Wojtynek N, Lustgarten S, Banerjee S. PO004LBA/#1515 Efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer following prior systemic therapy. 2023, a3-a4. DOI: 10.1136/ijgc-2023-igcs.4.Peer-Reviewed Original Research